Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566

Benzinga Newsdesk www.benzinga.com Positive 72.3%

Neg 0% Neu 0% Pos 72.3%

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.